WO2005048996A3 - Modified release dosage forms of skeletal muscle relaxants - Google Patents

Modified release dosage forms of skeletal muscle relaxants Download PDF

Info

Publication number
WO2005048996A3
WO2005048996A3 PCT/US2004/037266 US2004037266W WO2005048996A3 WO 2005048996 A3 WO2005048996 A3 WO 2005048996A3 US 2004037266 W US2004037266 W US 2004037266W WO 2005048996 A3 WO2005048996 A3 WO 2005048996A3
Authority
WO
WIPO (PCT)
Prior art keywords
skeletal muscle
dosage forms
release dosage
modified release
muscle relaxants
Prior art date
Application number
PCT/US2004/037266
Other languages
French (fr)
Other versions
WO2005048996A2 (en
Inventor
Gopi Venkatesh
James M Clevenger
Original Assignee
Eurand Inc
Gopi Venkatesh
James M Clevenger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34573847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005048996(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eurand Inc, Gopi Venkatesh, James M Clevenger filed Critical Eurand Inc
Publication of WO2005048996A2 publication Critical patent/WO2005048996A2/en
Publication of WO2005048996A3 publication Critical patent/WO2005048996A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T29/00—Metal working
    • Y10T29/49—Method of mechanical manufacture
    • Y10T29/49826—Assembling or joining

Abstract

A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population exhibits a pre-designed sustained release profile. Such a drug delivery system is designed for once--daily oral administration to maintain an adequate plasma concentration - time profile, thereby providing relief of muscle spasm associated with painful musculoskeletal conditions over a 24 hour period.
PCT/US2004/037266 2003-11-14 2004-11-09 Modified release dosage forms of skeletal muscle relaxants WO2005048996A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/713,929 2003-11-14
US10/713,929 US7387793B2 (en) 2003-11-14 2003-11-14 Modified release dosage forms of skeletal muscle relaxants

Publications (2)

Publication Number Publication Date
WO2005048996A2 WO2005048996A2 (en) 2005-06-02
WO2005048996A3 true WO2005048996A3 (en) 2005-09-15

Family

ID=34573847

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/037266 WO2005048996A2 (en) 2003-11-14 2004-11-09 Modified release dosage forms of skeletal muscle relaxants

Country Status (2)

Country Link
US (10) US7387793B2 (en)
WO (1) WO2005048996A2 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8197846B2 (en) * 2003-11-10 2012-06-12 Astellas Pharma Inc. Sustained release pharmaceutical composition
US8128958B2 (en) * 2003-11-10 2012-03-06 Astellas Pharma Inc. Sustained release pharmaceutical composition
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US8673352B2 (en) * 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
WO2007010508A2 (en) * 2005-07-22 2007-01-25 Ranbaxy Laboratories Limited Controlled release compositions of metaxalone
US8343546B2 (en) * 2005-09-13 2013-01-01 Coating Place, Inc. Ion exchange resin treated to control swelling
ES2700433T3 (en) 2005-12-13 2019-02-15 Incyte Holdings Corp Derivatives of pyrrolo [2,3-d] pyrimidine as inhibitors of Janus kinases
ITMI20061024A1 (en) * 2006-05-25 2007-11-26 Eurand Pharmaceuticals Ltd PELLETS BASED ON LIPOIC ACID
US9744137B2 (en) * 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
US8298576B2 (en) 2006-11-17 2012-10-30 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
AU2007329373B2 (en) * 2006-12-04 2013-06-20 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
ITMI20072051A1 (en) * 2007-10-23 2009-04-24 Chimico Internaz S P A In Brev PELLET BASED COMPOSITION OF LIPOIC ACID
US20090148532A1 (en) * 2007-12-06 2009-06-11 Venkatesh Gopi M Preparation of controlled release skeletal muscle relaxant dosage forms
US20100034968A1 (en) * 2008-08-07 2010-02-11 Vector Corporation Polymer coating process using dry glidant in a rotor processor
US8807070B2 (en) * 2008-08-07 2014-08-19 Vector Corporation Rotor processor for dry powders
US20100034967A1 (en) * 2008-08-07 2010-02-11 Vector Corporation Dry polymer layering using a rotor processor
WO2010099508A1 (en) 2009-02-26 2010-09-02 Theraquest Biosciences, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
TW201041607A (en) * 2009-05-01 2010-12-01 Eurand Inc Orally disintegrating tablet compositions comprising combinations of non-opioid and opioid analgesics
WO2010133961A1 (en) * 2009-05-22 2010-11-25 Inventia Healthcare Private Limited Extended release compositions of cyclobenzaprine
US8784884B2 (en) 2009-09-17 2014-07-22 Stephen Perrett Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency
CN102548544B (en) * 2009-10-09 2015-01-21 永进药品工业株式会社 Pharmaceutical composition with both immediate and extended release characteristics
SG10201407947WA (en) 2009-11-30 2015-01-29 Aptalis Pharmatech Inc Compressible-coated pharmaceutical compositions and tablets and methods of manufacture
ES2662588T3 (en) 2010-03-10 2018-04-09 Incyte Holdings Corporation Piperidin-4-IL azetidine derivatives as JAK1 inhibitors
US20130230586A1 (en) * 2010-10-02 2013-09-05 Link Research & Grants Corporation Treatment of Tinnitus and Related Auditory Dysfunctions
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
AU2012277375A1 (en) 2011-06-29 2014-01-30 Sun Pharmaceutical Industries Limited Multilayered dosage form
IN2012DE00193A (en) 2012-01-23 2015-06-12 Ranbaxy Lab Ltd
EA201590930A1 (en) 2012-11-15 2015-08-31 Инсайт Корпорейшн DOSAGE FORMS OF RUXOLITINIB WITH Slow Release.
WO2014167440A1 (en) 2013-03-26 2014-10-16 Wockhardt Limited Modified release pharmaceutical compositions of cyclobenzaprine or salts thereof
SI3030227T1 (en) 2013-08-07 2020-08-31 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
WO2015150948A1 (en) 2014-03-29 2015-10-08 Wockhardt Limited Modified release solid oral pharmaceutical compositions of cyclobenzaprine or a salt thereof
CN104473908A (en) * 2014-11-21 2015-04-01 哈尔滨圣吉药业股份有限公司 Cyclobenzaprine hydrochloride sustained release pellets and preparation method thereof
CN104523655B (en) * 2014-12-22 2017-04-19 青岛正大海尔制药有限公司 Cyclobenzaprine hydrochloride sustained-release capsules
US20170056342A1 (en) * 2015-08-31 2017-03-02 Apotex Technologies Inc. Extended Release Dosage Form Comprising Cyclobenzaprine Hydrochloride
CN106890129A (en) * 2015-12-18 2017-06-27 健乔信元医药生技股份有限公司 The extended release dosage form of the general woods of ring benzyl
CA3013123A1 (en) 2016-02-04 2017-08-10 Cinrx Pharma, Llc Deuterated domperidone compositions and methods for therapy of disorders
CN105596313B (en) * 2016-02-17 2018-06-29 新乡医学院第一附属医院 A kind of capsule preparations for treatment insomnia with reversed pharmacological function
ES2958616T3 (en) 2017-03-08 2024-02-12 Cinrx Pharma Llc Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
US11364226B2 (en) 2017-06-30 2022-06-21 Cinrx Pharma, Llc Deuterated domperidone compositions, methods, and preparation
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4728513A (en) * 1985-07-31 1988-03-01 Zyma Sa Granular delayed-release form of pharmaceutically active substances
US4851228A (en) * 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
WO2001015668A1 (en) * 1999-09-02 2001-03-08 Nostrum Pharmaceuticals, Inc. Controlled release pellet formulation
WO2003020242A1 (en) * 2001-08-29 2003-03-13 Srl Technologies, Inc. Sustained release preparations

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US481228A (en) * 1892-08-23 Carding engine for grinding revolving flats when in situ
US3155590A (en) 1962-08-02 1964-11-03 Ncr Co Encapsulation process and its product
US3341416A (en) 1963-12-11 1967-09-12 Ncr Co Encapsulation of aspirin in ethylcellulose and its product
US3488418A (en) 1965-11-18 1970-01-06 Sterling Drug Inc Sustained relief analgesic composition
US3882246A (en) 1971-05-21 1975-05-06 Merck & Co Inc Treatment of skeletal muscle disorders with cyclobenzaprine
GB2058562B (en) 1979-09-14 1983-11-30 Beecham Group Ltd Pharmaceutical compositions containing paracetamol and ascorbic acid
JPS57500432A (en) 1980-03-20 1982-03-11
US5366738A (en) 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
US4882167A (en) 1983-05-31 1989-11-21 Jang Choong Gook Dry direct compression compositions for controlled release dosage forms
US4851229A (en) 1983-12-01 1989-07-25 Alza Corporation Composition comprising a therapeutic agent and a modulating agent
DK62184D0 (en) 1984-02-10 1984-02-10 Benzon As Alfred DIFFUSION COATED POLYDEPOT PREPARATION
US4590062A (en) 1984-04-16 1986-05-20 Tech Trade Corp. Dry direct compression compositions for controlled release dosage forms
US4968507A (en) 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
IT1176853B (en) 1984-10-02 1987-08-18 Eurand Spa PROCEDURE FOR OBTAINING A CONTROLLED RELEASE FORMULATION OF WATER SOLUBLE COMPONENTS
US4780463A (en) 1984-12-26 1988-10-25 Analgesic Associates Analgesic, anti-inflammatory and skeletal muscle relaxant compositions comprising non-steroidal anti-inflammatory drugs and musculoskeletal relaxants and methods of using same
US4780319A (en) 1985-07-08 1988-10-25 Merck & Co., Inc. Organic acids as catalysts for the erosion of polymers
IT1188212B (en) * 1985-12-20 1988-01-07 Paolo Colombo SYSTEM FOR THE RELEASE SPEED OF ACTIVE SUBSTANCES
GB8616669D0 (en) 1986-07-09 1986-08-13 Merk Sharpe & Dohme Ltd Pharmaceutical compositions
US4743248A (en) 1986-08-11 1988-05-10 Alza Corporation Dosage form for delivering acid sensitive beneficial agent
US4789549A (en) 1987-03-09 1988-12-06 Warner-Lambert Company Sustained release dosage forms
US4814183A (en) 1987-08-31 1989-03-21 Merck & Co., Inc. Device for the controlled release of drugs with Donnan-like modulation by charged insoluble resins
US4795644A (en) 1987-08-03 1989-01-03 Merck & Co., Inc. Device for pH independent release of drugs through the Donnan-like influence of charged insoluble resins
IT1216570B (en) 1988-04-08 1990-03-08 Vectorpharma Int CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION AND PROCEDURE FOR THEIR PREPARATION.
US4996047A (en) 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
IT1241417B (en) 1990-03-06 1994-01-14 Vectorpharma Int THERAPEUTIC COMPOSITIONS WITH CONTROLLED RELEASE OF DRUGS SUPPORTED ON CROSS-LINKED POLYMERS AND COATED WITH POLYMER FILM, AND THEIR PREPARATION PROCESS
GB2253346A (en) 1991-02-22 1992-09-09 John Rhodes Delayed release oral dosage forms for treatment of intestinal disorders
US5102668A (en) 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
EP0518263A1 (en) 1991-06-10 1992-12-16 Hoechst-Roussel Pharmaceuticals Incorporated Micropellets and a process for their manufacture
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5543154A (en) 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
FI920206A0 (en) 1992-01-17 1992-01-17 Pekka Untamo Heino MEDICINSK ANVAENDNING, MEDICINSKT FOERFARANDE OCH PREPARAT.
US5350584A (en) 1992-06-26 1994-09-27 Merck & Co., Inc. Spheronization process using charged resins
US5422122A (en) 1992-08-04 1995-06-06 Eurand America, Incorporated Controlled release potassium chloride tablet
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
AU5995094A (en) * 1993-01-29 1994-08-15 Merck & Co., Inc. Ciclobenzaprine-caffeine combination as a muscle relaxant
US5582838A (en) 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
US5534263A (en) 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
US5980948A (en) 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
ATE277739T1 (en) 1996-10-28 2004-10-15 Gen Mills Inc EMBEDDING AND ENCAPSULATING PARTICLES FOR CONTROLLED DELIVERY
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
IL128043A (en) 1997-05-30 2004-08-31 Osmotica Corp Multi-layered osmotic device for controlled delivery of active agents
US6028163A (en) 1997-06-27 2000-02-22 Guilford Pharmaceuticals Inc. Solution polymerization of high molecular weight poly(phosphoesters) in toluene
EP1017370B1 (en) 1997-09-11 2003-10-29 Nycomed Danmark ApS MODIFIED RELEASE MULTIPLE-UNITS COMPOSITIONS OF NON-STEROID ANTI-INFLAMMATORY DRUG SUBSTANCES (NSAIDs)
WO1999018937A1 (en) 1997-10-16 1999-04-22 Merck & Co., Inc. New cyclobenzaprine composition
KR100257579B1 (en) 1997-11-13 2000-06-01 전주범 Method and apparatus for displaying a pager message in an internet tv
WO1999030671A2 (en) 1997-12-15 1999-06-24 Ron Eyal S Aspected particles for oral delivery
US6191162B1 (en) 1998-05-28 2001-02-20 Medical Research Institute Method of reducing serum glucose levels
US6673367B1 (en) * 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6358944B1 (en) 1999-08-13 2002-03-19 Vela Pharmaceuticals, Inc. Methods and compositions for treating generalized anxiety disorder
US6451345B1 (en) 2000-01-20 2002-09-17 Eurand Pharmaceuticals Ltd. Functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6451645B1 (en) * 2000-07-12 2002-09-17 Denso Corp Method for manufacturing semiconductor device with power semiconductor element and diode
US6344215B1 (en) 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
US6500454B1 (en) 2001-10-04 2002-12-31 Eurand Pharmaceuticals Ltd. Timed, sustained release systems for propranolol
US6663888B2 (en) 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
WO2004064772A2 (en) 2003-01-14 2004-08-05 Alza Corporation Methods and dosage forms with modified viscosity layers
US20040197407A1 (en) 2003-02-11 2004-10-07 Ramkumar Subramanian Methods and dosage forms with modified layer geometry
US7632521B2 (en) 2003-07-15 2009-12-15 Eurand, Inc. Controlled release potassium chloride tablets
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851228A (en) * 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
US4728513A (en) * 1985-07-31 1988-03-01 Zyma Sa Granular delayed-release form of pharmaceutically active substances
WO2001015668A1 (en) * 1999-09-02 2001-03-08 Nostrum Pharmaceuticals, Inc. Controlled release pellet formulation
WO2003020242A1 (en) * 2001-08-29 2003-03-13 Srl Technologies, Inc. Sustained release preparations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AKIMOTO MASAYUKI ET AL: "Evaluation of sustained-release granules of chlorphenesin carbamate in dogs and humans", INTERNATIONAL JOURNAL OF PHARMACEUTICS (AMSTERDAM), vol. 100, no. 1-3, 1993, pages 133 - 142, XP002330219, ISSN: 0378-5173 *

Also Published As

Publication number Publication date
US9399025B2 (en) 2016-07-26
US7790199B2 (en) 2010-09-07
US7387793B2 (en) 2008-06-17
US20080124399A1 (en) 2008-05-29
US20090017126A1 (en) 2009-01-15
US8877245B2 (en) 2014-11-04
US20130209567A1 (en) 2013-08-15
US20150093436A1 (en) 2015-04-02
US20110217384A1 (en) 2011-09-08
US7544372B2 (en) 2009-06-09
US20050106247A1 (en) 2005-05-19
WO2005048996A2 (en) 2005-06-02
US9375410B2 (en) 2016-06-28
US7829121B2 (en) 2010-11-09
US20150196505A1 (en) 2015-07-16
US20160361274A1 (en) 2016-12-15
US20080124398A1 (en) 2008-05-29
US20090017127A1 (en) 2009-01-15
US7820203B2 (en) 2010-10-26

Similar Documents

Publication Publication Date Title
WO2005048996A3 (en) Modified release dosage forms of skeletal muscle relaxants
MXPA04003234A (en) Timed, sustained release multi-particulate dosage forms of propranolol.
CA2494234A1 (en) Methods and dosage forms for controlled delivery of paliperidone
SE1660037T5 (en)
WO2006125819A3 (en) Oral microparticulate, anti-misuse drug formulation
TWI265812B (en) Pharmaceutical safety dosage forms
WO2006022996A3 (en) Dosage form containing multiple drugs
EA200700049A1 (en) PREPARATIVE FORMS OF ORAL MEDICINAL FORMS OF MEMANTINE WITH MODIFIED SURVIVAL
HRP20120587T1 (en) Tamper-resistant products for delivery of opioids and other drugs apt to be abused
CA2264852A1 (en) Use of methylphenidate or a pharmaceutically acceptable salt thereof
EP1469838A4 (en) Manufacture of oral dosage forms delivering both immediate release and sustained release drugs
WO2001019337A3 (en) Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
WO2003103637A3 (en) Modified release, multiple unit drug delivery systems
IL174562A0 (en) Oros push-stick for controlled delivery of active agent
HRP20120264T1 (en) Pharmaceutical compositions of a neuroactive steroid and uses thereof
WO2007078443A3 (en) Methods of treating unwanted immune response with random copolymers
AP2002002410A0 (en) Hydrodynamically Balancing Oral Drug Delivery System
WO2005120542A3 (en) Methods of treating disease with random copolymers
HUP0500097A3 (en) Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
WO2006060325A3 (en) Coated drug delivery formulations
BR0013719A (en) Controlled-release oral dosage, suitable for oral administration
IL179177A (en) Pharmaceutical composition comprising acyclovir and a delivery agent, a dosage unit, use of acyclovir in the preparation of the pharmaceutical composition, use of the pharmaceutical composition in the preparation of a medicament and a method of preparing the pharmaceutical composition
TW200509985A (en) Drug delivery system for sub-Tenon administration of fine particles
WO2003099214A3 (en) Biguanide formulations
ES2169980A1 (en) Microcapsules for sustained release of drugs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase